Watch IMNM. Know when insiders buy.
One email the day a filing lands. Free.
IMNM
Immunome Inc.
23.95
−0.60 −2.44%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · insiders 35, shorts 78
Insiders, 90 days
−$334K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.7BP/E —DIV YIELD —FCF YIELD -8.05%REV TTM $0 −100.0%NET INCOME −$254.3MNET CASH $217.2M52W 8.99 – 29.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$78.1M | −$73.1M | — | -0.65 | −$61.7M | $2.2M | −$63.9M | Aug 11 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$59.3M | −$53.8M | — | -0.48 | −$58.6M | $3M | −$61.6M | Aug 11 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$72.9M | −$69.9M | — | -0.75 | −$48M | $4M | −$52M | Mar 3 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$60.1M | −$57.5M | — | -0.65 | −$40.5M | $1.1M | −$41.6M | Nov 6 |
| Q2 2025 · Jun 30 | $4M | +69.8% | — | −$46.5M | −$43.4M | — | -0.50 | −$49.4M | $905K | −$50.3M | Aug 11 |
| Q1 2025 · Mar 31 | $2.9M | +184.4% | — | −$44.6M | −$41.6M | — | -0.52 | −$53.1M | $3.7M | −$56.7M | Aug 11 |
| Q4 2024 · Dec 31derived | $2.7M | −28.4% | — | −$83M | −$80.2M | — | -1.28 | −$42.1M | $1.1M | −$43.2M | Mar 3 |
| Q3 2024 · Sep 30 | $2.9M | −18.4% | — | −$50.5M | −$47.1M | — | -0.78 | −$34.2M | $1.5M | −$35.7M | Nov 6 |
| Q2 2024 · Jun 30 | $2.4M | — | — | −$40M | −$36.1M | — | -0.60 | −$23.4M | $2.3M | −$25.7M | Nov 6 |
| Q1 2024 · Mar 31 | $1M | — | — | −$132.3M | −$129.5M | — | -2.51 | −$11.2M | $2.2M | −$13.3M | Nov 6 |
| Q4 2023 · Dec 31derived | $3.8M | — | — | −$94.7M | −$92.6M | — | -4.22 | −$17.5M | $349K | −$17.8M | Mar 19 |
| Q3 2023 · Sep 30 | $3.6M | — | — | −$4.6M | −$4.3M | — | -0.36 | −$8.6M | $36K | −$8.7M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.9M | — | −$224.1M | −$212.4M | -3060.0% | -2.43 | −$190.9M | $9.7M | −$200.6M | — | — |
| FY2024 · to Dec 31 | $9M | — | −$305.8M | −$293M | -3240.4% | -5.00 | −$110.8M | $7.2M | −$118M | — | — |
| FY2023 · to Dec 31 | $14M | — | −$109.5M | −$106.8M | -761.9% | -5.38 | −$7.6M | $831K | −$8.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$36.9M | −$36.9M | — | -3.09 | −$28.7M | $248K | −$28.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$25.2M | −$24.7M | — | -2.14 | −$18.2M | $79K | −$18.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$12.3M | −$17.8M | — | -5.26 | −$12.1M | $586K | −$12.7M | — | — |
Every number comes from Immunome Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.